title: Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
abstract: The involvement of the protein α-synuclein (SNCA) in the pathogenesis of Parkinson's disease is strongly supported by the facts that (i) missense and copy number mutations in the SNCA gene can cause inherited Parkinson's disease; and (ii) Lewy bodies in sporadic Parkinson's disease are largely composed of aggregated SNCA. Unaffected heterozygous carriers of Gaucher disease mutations have an increased risk for Parkinson's disease. As mutations in the GBA gene encoding glucocerebrosidase (GBA) are known to interfere with lysosomal protein degradation, GBA heterozygotes may demonstrate reduced lysosomal SNCA degradation, leading to increased steady-state SNCA levels and promoting its aggregation. We have created mouse models to investigate the interaction between GBA mutations and synucleinopathies. We investigated the rate of SNCA degradation in cultured primary cortical neurons from mice expressing wild-type mouse SNCA, wild-type human SNCA, or mutant A53T SNCA, in a background of either wild-type Gba or heterozygosity for the L444P GBA mutation associated with Gaucher disease. We also tested the effect of this Gaucher mutation on motor and enteric nervous system function in these transgenic animals. We found that human SNCA is stable, with a half-life of 61 h, and that the A53T mutation did not significantly affect its half-life. Heterozygosity for a naturally occurring Gaucher mutation, L444P, reduced GBA activity by 40%, reduced SNCA degradation and triggered accumulation of the protein in culture. This mutation also resulted in the exacerbation of motor and gastrointestinal deficits found in the A53T mouse model of Parkinson's disease. This study demonstrates that heterozygosity for a Gaucher disease-associated mutation in Gba interferes with SNCA degradation and contributes to its accumulation, and exacerbates the phenotype in a mouse model of Parkinson's disease.
authors.affiliation: 1 Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA nussbaumr@humgen.ucsf.edu.
authors.forename: Ianai
authors.initials: I
authors.lastname: Fishbein
authors.affiliation: 1 Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
authors.forename: Yien-Ming
authors.initials: YM
authors.lastname: Kuo
authors.affiliation: 2 Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA.
authors.forename: Benoit I
authors.initials: BI
authors.lastname: Giasson
authors.affiliation: 1 Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Nussbaum
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005776:Gaucher Disease / Q000150:complications / Q000235:genetics*; D015870:Gene Expression; D005838:Genotype; D005962:Glucosylceramidase / Q000235:genetics*; D006579:Heterozygote; D057507:Mice, 129 Strain; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics*; D010300:Parkinson Disease / Q000150:complications / Q000235:genetics*; D010641:Phenotype; D051844:alpha-Synuclein / Q000235:genetics* / Q000378:metabolism
chemical_list: D051844:alpha-Synuclein; D005962:Glucosylceramidase
keywords: Gaucher disease; Parkinson’s disease; alpha-synuclein; lysosomal protein degradation; mouse model